We aim to be pioneers investing in data-driven platform companies at the intersection of healthcare, life sciences, and deep technology — the next Industrial Revolution profoundly impacting humanity.
Tell us about yourself?
My personal mission (Ikigai 生き甲斐) is to advance healthcare and life sciences.
I am the founder of two funds. The first fund, Neue Fund, is a 2018 vintage, top-performing fund, with 40 early-stage companies valued at ~$5 billion. The Fund currently has an IPO (space tech), acquisition (organ printing), and second IPO filing (AI drug discovery & development), among other achievements. The second fund, Harmonix Fund I LP, 2021 vintage, currently has more than ten investments ranging from Tech+Bio (AI-driven biotechnology, synthetic biology) to healthcare technology, space, and critical infrastructure.
I am also 4th generation entrepreneur from a Top 500 German family business.
If you could give one piece of advice to other investors, what would it be?
Create a vision for your investment portfolio that isn’t only about profit but benefits others as well. Due diligence is everything. We’ve reviewed 5,000+ deals to date and have 250+ co-investors and we are always open to more co-investment on top deals.
If you could give one piece of advice to startup founders looking to get funding from you, what would you say?
Majority of our investments have $1M-$20M+ revenue traction with significant upside potential (10x+). We are willing to invest in early to late stage companies who have dedicated teams with a proven track record.
What do you look for in the founding team of the startups you invest in?
We look for a multi-disciplinary team with experienced track records.
Is there a trait you have noticed predicts success in your investments?
A $1M-$20M+ revenue traction, a strong focused internal fund team and dedicated, passionate founders.
How has COVID impacted your investment strategy and existing investments?
It has given us the time to refine our diligence process and has created an even stronger investment focus and awareness of healthcare and life sciences and the need to innovate and redefine and critical infrastructure.
What do you see as the emerging areas of technology that you are looking to invest in?
We are currently investing in data-driven platform companies at the intersection of healthcare, life sciences, and deep tech. We think that the convergence of these three sectors represents the next Industrial Revolution and is ushering in a new era of scientific advancement.
How do you source new investment opportunities?
We source companies from the world’s top accelerators, incubators, universities, academic research labs, co-investor syndicates, and startup ecosystems.
We’ve reviewed 5,000+ deals to date between two funds and have 250+ co-investors.
How do people get involved/buy into your vision?
Please send pitch decks to Cofield Mundi at [email protected].